Cognitive decline, the primary clinical phenotype of Alzheimer’s disease (AD), is currently attributed mainly to amyloid and tau protein deposits. However, a growing body of evidence is converging on brain lipids, and blood–brain barrier (BBB) dysfunction, as crucial players involved in AD development. The critical role of lipids metabolism in the brain and its vascular barrier, and its constant modifications particularly throughout AD development, warrants investigation of brain lipid metabolism as a high value therapeutic target. Yet, there is limited knowledge on the biochemical and structural roles of lipids in BBB functionality in AD. Within this framework, we hypothesize that the ApoE4 genotype, strongly linked to AD risk and progression, may be related to altered fatty acids composition in the BBB. Interestingly, alpha linolenic acid (ALA), the precursor of the majoritarian brain component docosahexaenoic acid (DHA), emerges as a potential novel brain savior, acting via BBB functional improvements, and this may be primarily relevant to ApoE4 carriers.
Gallstones, mostly cholesterol stones, affect some 15% of the population. Oral bile salts dissolve human cholesterol gallstones, but with low efficacy, and surgery remains the main therapeutic option. Fatty acid bile acid conjugates (FABACs) were shown to prevent formation of cholesterol gallstones in experimental animals. The aim of this study was to test whether these compounds could dissolve preexisting cholesterol gallstones via oral administration. Inbred, gallstone-susceptible C57J/L mice were given a lithogenic diet for 2 months, and the presence of gallstones was ascertained. The mice were then switched to a regular diet while part of them were given in addition C20-FABAC, by gavage, at a dose of 0.5 or 3 mg per animal per day. All mice tested had cholesterol gallstones after 2 months on the lithogenic diet. In study I, after 2 months on the regular diet, 3 of 4 (75%) of the controls had gallstones, whereas none of the 6 FABAC-fed animals (3 mg/d) had stones (P = .033). In study II, evaluating 2 FABAC doses, after 2 months on the regular diet, 8 of 8 (100%) of the controls had gallstones, which were found in 2 of 7 (28%) and 1 of 8 (12%) of the mice supplemented with 0.5 mg/d (P = .007) or 3 mg/d (P = .001) FABAC, respectively. On a molar basis, the dose of 0.5 mg FABAC is equivalent to 14 mg/kg/d of a bile acid. In conclusion, FABACs given orally can dissolve preexisting cholesterol gallstones in mice. This was accomplished with a dose of FABAC equivalent to the dose of bile acids used in human gallstone dissolution.
1 October 2021 in Prostaglandins, Leukotrienes and Essential Fatty Acids
The APOE4 allele significantly increases Alzheimer's disease (AD) risk, often linked to brain lipid imbalance. This study investigated lipid profiles in the brain parenchyma and brain blood vessels (BBV) of APOE3 and APOE4-humanized female mice, assessing the protective effects of an alpha-linolenic acid (ALA)-rich diet on lipid composition and memory in APOE4 mice. Mice received either a Control or an ALA-rich flaxseed oil diet for six months. Lipid profiles were analyzed in brain parenchyma, BBV, plasma, and liver, alongside memory performance. In vitro studies explored human brain endothelial cell conversion of ALA to docosahexaenoic acid (DHA). APOE4 mice, compared to APOE3 controls, exhibited significant lipid depletion in brain parenchyma, including reduced cholesterol (32%), phospholipids (10%), and DHA (57%). The ALA-rich diet beneficially restored lipid levels in APOE4 brain parenchyma, increased DHA-containing phospholipids, and improved memory. This diet also elevated n-3 fatty acids and DHA within the BBV, particularly in APOE4 phosphatidylserine, and upregulated lipid-related genes (PLA2, LDLR). In vitro data confirmed brain endothelial cells synthesize DHA via the ∆6 desaturase pathway, a process suppressed by desaturase inhibitors or external DHA. Collectively, these findings suggest the BBV acts as a crucial hub for lipid homeostasis. An ALA-rich diet effectively mitigates lipid imbalance in APOE4 mice by promoting lipid unsaturation, enhancing DHA synthesis and its incorporation into complex lipids, thereby improving cognitive performance. This research positions dietary ALA as a promising nutritional intervention for APOE4 carriers.